Genentech Tissue Product Sales Stall; Rituxan Driving Immunology
Executive Summary
Sales growth has stalled for Genentech's tissue growth and repair products, with U.S. sales in the fourth quarter of 2007 nearly identical to third quarter totals. Compared to the fourth quarter of 2006, U.S. sales were down 5 percent
You may also be interested in...
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer
Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions
Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005